POXEL |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.637 EUR | -4.50% |
|
-6.46% | +15.61% |
| 04-11 | Poxel: CDC falls below the 10% threshold | CF |
| 02-15 | Poxel S.A. Reports Unaudited Revenue Results for the Fourth Quarter and Full Year Ended December 31, 2023 | CI |
| Sales 2021 | 13.4M 14.56M 1.15B | Sales 2022 | 674K 732K 57.72M | Capitalization | 27.16M 29.52M 2.33B |
|---|---|---|---|---|---|
| Net income 2021 | -23M -25M -1.97B | Net income 2022 | -31M -33.69M -2.65B | EV / Sales 2021 | 10.7 x |
| Net Debt 2021 | 3M 3.27M 257M | Net Debt 2022 | 32.74M 35.57M 2.8B | EV / Sales 2022 | 88.9 x |
| P/E ratio 2021 |
-5.92
x | P/E ratio 2022 |
-0.87
x | Employees | 15 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 99.57% |
More Fundamentals
* Assessed data
More news
Latest transcript on Poxel
More press releases
More news
| 1 day | -4.50% | ||
| 1 week | -6.46% | ||
| Current month | +4.43% | ||
| 1 month | -2.60% | ||
| 3 months | +23.69% | ||
| 6 months | +76.45% | ||
| Current year | +15.61% |
1 week
0.61
0.69
1 month
0.570.90
Current year
0.360.90
1 year
0.300.95
3 years
0.307.75
5 years
0.3013.80
10 years
0.3017.74
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 61 | 05/03/09 | |
Sebastien Bolze
FOU | Founder | - | 05/03/09 |
| Founder | - | 05/03/09 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Richard Kender
BRD | Director/Board Member | 68 | 11/03/15 |
Pascale Boissel
BRD | Director/Board Member | 57 | 04/03/15 |
Thomas Kuhn
FOU | Founder | 50 | 05/03/09 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 17/05/24 | 0.637 | -4.50% | 438,634 |
| 16/05/24 | 0.667 | -0.45% | 141,986 |
| 15/05/24 | 0.67 | -0.89% | 118,973 |
| 14/05/24 | 0.676 | +1.65% | 302,878 |
| 13/05/24 | 0.665 | -2.35% | 200,171 |
Real-time Euronext Paris, May 17, 2024 at 04:35 pm
More quotes
Poxel is a biopharmaceutical company specializing in developing innovative treatments for metabolic diseases, including non-alcoholic steatohepatitis (NASH) and rare diseases.
TWYMEEG® (Imeglimine), Poxel's lead product and the first in its class of medicines, which targets mitochondrial dysfunction, has been marketed in Japan for the treatment of type 2 diabetes.
For the treatment of NASH, the PXL065 met its primary endpoint in a streamlined Phase II trial, and PXL770 has completed a Phase IIa proof-of-concept study by reaching its objectives. In adrenoleukodystrophy (ALD), a rare inherited metabolic disease, the company intends to initiate Phase IIa proof-of-concept studies with the PXL065 and the PXL770 in patients with adrenomyeloneuropathy (AMN).
Calendar
28/08/2024
- Q2 2024 Sales and Revenue Release
| 1st Jan change | Capi. | |
|---|---|---|
| +15.61% | 26.84M | |
| +9.42% | 115B | |
| +11.84% | 106B | |
| -1.05% | 21.96B | |
| -14.15% | 21.84B | |
| -5.29% | 19.21B | |
| -4.16% | 18.08B | |
| -38.29% | 17.71B | |
| +7.99% | 14.32B | |
| +36.24% | 12.42B |
- Stock Market
- Equities
- POXEL Stock
